IDEXX Laboratories, Inc. (IDXX) posted third-quarter 2024 earnings per share (EPS) of $2.80, up 10.7% year over year. The figure surpassed the Zacks Consensus Estimate by 4.1%.Comparable constant-currency EPS of $2.79 improved 12% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, IDXX stock fell 3.1% at the pre-market trading today.IDEXX’s Revenues in DetailQuarterly revenues increased 6.6% year over year (up 6% organically) to $975.5 ...

For the quarter ended September 2024, Idexx Laboratories (IDXX) reported revenue of $975.54 million, up 6.6% over the same period last year. EPS came in at $2.80, compared to $2.53 in the year-ago quarter.The reported revenue represents a surprise of -0.41% over the Zacks Consensus Estimate of $979.59 million. With the consensus EPS estimate being $2.69, the EPS surprise was +4.09%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wal ...

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.09%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.87 per share when it actually produced earnings of $2.44, delivering a surprise of -14.98%.Over ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Third Quarter Results ▪ Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. ▪ Organic revenue growth supported by benefits from IDEXX execution drivers including continued solid new business gains and double-digit year-over-year global premium installed base growth. ▪ Delivers EPS of $2 ...

In its upcoming report, Idexx Laboratories (IDXX) is predicted by Wall Street analysts to post quarterly earnings of $2.69 per share, reflecting an increase of 6.3% compared to the same period last year. Revenues are forecasted to be $979.05 million, representing a year-over-year increase of 6.9%. Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of th ...

IDEXX Laboratories, Inc. (IDXX) is set to release third-quarter 2024 results on Oct. 31, before the opening bell. The company posted adjusted earnings per share (EPS) of $2.44 in the last reported quarter, which missed the Zacks Consensus Estimate by 14.98%. IDEXX Laboratories beat earnings estimates in three of the trailing four quarters and missed in one, the average surprise being 1.51%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. IDXX's Q3 Estimates For the third quarter of 2 ...

It has been about a month since the last earnings report for Idexx Laboratories (IDXX) . Shares have added about 0.9% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Idexx due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. IDEXX Misses Q2 Earnings Estimates, Narro ...

Oliver Rossi In my 'Sell' report published in April 2024, I highlighted IDEXX's (NASDAQ:IDXX) high-quality business in consumables and software, as well as the stock's hefty valuation. IDEXX reported its Q2 result on August 6th, lowering the full-year organic revenue growth to 6.2% - 7.8% for FY24. The guidance cut is primarily caused by reduced U.S. clinical visits. While I think the lower clinical visits are maero-driven and short-term in nature, the stock price remains overvalued and has not fully accoun ...

Revenue Performance - Total Company revenue for the three months ended June 30, 2024, was $1,003,578,000, representing a 6.4% increase compared to $943,630,000 in the same period of 2023[138]. - Organic revenue growth for the same period was 6.7%, driven by higher recurring revenue in CAG Diagnostics and increased volumes globally[138]. - CAG segment revenue reached $922,298,000, with a 6.7% organic growth rate, while the U.S. market contributed $628,684,000, reflecting a 5.2% organic growth[138]. - Water segment revenue increased to $46,726,000, with a 9.5% organic growth rate, primarily due to higher realized prices and increased volumes in the U.S. and Europe[138]. - LPD segment revenue was $30,306,000, with a 2.9% organic growth rate, supported by higher realized prices and volume growth in North America and Europe[138]. - Total revenues for the three months ended June 30, 2024, were $1,003,578, representing a 6.4% increase from $943,630 in the same period of 2023[140]. - CAG segment net revenue was $922,298, a 6.4% increase from $866,652, with organic revenue growth of 6.7%[144]. - Total company revenues for the six months ended June 30, 2024, reached $1,967,673 thousand, reflecting a 6.7% increase from $1,843,825 thousand in the same period of 2023[164]. - CAG segment revenues grew to $1,811,583, reflecting a 6.9% increase from $1,693,931 in 2023[172]. - Water segment revenue grew to $89,797, a 9.6% increase, attributed to higher realized prices and volumes[175]. Profitability Metrics - Gross profit increased to $619,159, with a gross profit margin of 61.7%, up from 60.7% in the prior year, reflecting a 100 basis point improvement[140]. - Gross profit for the total company increased to $1,212,229 thousand, with a gross profit margin of 61.6%, up from 60.5% in the previous year[164]. - Gross profit for the Water segment rose by 5.8% to $32,074,000, with a gross profit margin of 68.6%, down from 70.5% in the previous year[151]. - Livestock, Poultry and Dairy (LPD) segment revenues grew by 1.3% to $30,306,000, while gross profit decreased by 3.3% to $15,558,000, resulting in a gross profit margin of 51.3%[154]. - Gross profit decreased to $30,792,000, representing a gross profit margin of 52.6%, down from 52.7% in 2023[178]. Operating Expenses - Operating expenses rose to $355,358, a 28.4% increase from $276,706, primarily driven by a $61.5 million litigation expense and higher personnel costs[141]. - Total operating expenses for the Water segment increased by 10.2% to $11,570, driven by higher sales and marketing costs[151]. - Operating expenses increased by 21.9% to $594,061, driven by a significant rise in general and administrative expenses[173]. - General and administrative expenses surged by 56.0% to $249,267 thousand, primarily due to a significant litigation expense[165]. - Operating expenses totaled $649,470, a 20.4% increase from $539,278 in 2023, driven by significant increases in general and administrative expenses[165]. Cash Flow and Debt Management - Cash and cash equivalents as of June 30, 2024, were $401.6 million, a decrease from $453.9 million as of December 31, 2023[186]. - Net cash provided by operating activities increased to $446,897,000 for the six months ended June 30, 2024, compared to $384,226,000 in the same period of 2023[190]. - Cash used by investing activities was $139.9 million during the six months ended June 30, 2024, primarily due to the acquisition of a software business[193]. - Cash used by financing activities totaled $354.3 million, which included $370.3 million for repurchases of common stock[193]. - The company had $250.0 million in outstanding borrowings under its Credit Facility as of June 30, 2024[195]. - The consolidated leverage ratio as of June 30, 2024, was 0.74, with total debt of $944.855 million and Adjusted EBITDA of $1,279.423 million[201]. - The net debt to Adjusted EBITDA ratio as of June 30, 2024, was 0.43, with net debt of $548.219 million[201]. - Interest expense decreased to $8.1 million for the three months ended June 30, 2024, down from $10.5 million in the prior year, attributed to lower average debt levels[159]. - Interest expense decreased to $16.0 million for the six months ended June 30, 2024, down from $23.7 million in the prior year[184]. Foreign Currency Impact - The overall impact of foreign currency exchange rates decreased revenue growth by 0.7%[138]. - The overall change in foreign currency exchange rates negatively impacted revenue growth by 0.4%[162]. - The overall impact of foreign currency exchange rates was not significant to revenue growth across segments[169]. Research and Development - Research and development expenses increased by 19.2% to $55,450, reflecting higher project costs and personnel-related expenses[140]. - Research and development expenses across segments increased by 20.3% to $98,892, reflecting higher project and personnel-related costs[172]. - Research and development expenses increased by 18.6% to $108,085, reflecting higher project costs and personnel-related expenses[164]. Market and Segment Insights - The company operates through three primary segments: Companion Animal Group (CAG), Water, and Livestock, Poultry, and Dairy (LPD)[127]. - The company develops and distributes products primarily for veterinary, livestock, poultry, dairy, and water testing sectors[126]. - The decline in the LPD business was mainly due to lower demand in China, partially offset by higher realized prices and volume growth in the U.S. and Europe[162]. - The Water business experienced revenue growth due to higher realized prices and increased volumes in the U.S. and Europe, while LPD faced a decline in demand in China[162]. Forward-Looking Statements - Forward-looking statements indicate potential impacts from macroeconomic events, including geopolitical instability and inflationary pressures[203].

Tuesday, Idexx Laboratories Inc IDXX reported second-quarter adjusted EPS of $3.02, up 15% year-overyear, beating the consensus of $2.88. The company reported sales of $1 billion, an increase of 6% as reported and 7% organically, almost in line with the consensus of $1.01 billion. The revenue growth was driven by Companion Animal Group growth of 6% as reported and 7% organic and Water revenue growth of 9% as reported and 10% organic. Related: Aging Pet Population Is 'Solid Longer-Term Tailwind' For Idexx La ...